Lassa fever (LF) is a deadly viral hemorrhagic fever disease that is endemic in several countries in West Africa. It is caused by Lassa virus (LASV), which has been estimated to be responsible for approximately 300,000 infections and 5000 deaths annually. LASV is a highly pathogenic human pathogen without effective therapeutics or FDA-approved vaccines. Here, we aim to provide a literature review of the current understanding of the basic mechanism of immune responses to LASV infection in animal models and patients, as well as to several of its candidate vaccines.
Bibliographical noteFunding Information:
The authors would like to apologize to investigators whose work might have been unintentionally omitted from this review article. The corresponding author (H.L.) wishes to dedicate this article in loving memory of his eldest brother, Henry Lee. Funding support for Lassa virus work in the Ly laboratory was provided in parts by NIH grants R56 AI091805, R01 AI093580, R01 AI131586, and U19 AI171954. H.M. was supported in parts by the NIH T32 AI83196, the Minnesota Drive Global Food Ventures (MnDRIVE GFV) Graduate Professional Development Program, and the J.B. and J.N. Moe Graduate Fellowship.
© 2022 by the authors.
- Lassa virus
- hemorrhagic fevers
PubMed: MeSH publication types
- Journal Article